Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Mar;53(3):415-21.
doi: 10.1002/mus.24776. Epub 2015 Dec 15.

Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity

Elie Paul Elovic  1 , Michael C Munin  2 , Petr Kaňovský  3 , Angelika Hanschmann  4 , Reinhard Hiersemenzel  4 , Christina Marciniak  5
Affiliations
Randomized Controlled Trial

Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity

Elie Paul Elovic et al. Muscle Nerve. 2016 Mar.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Muscle Nerve. 2016 Jun;54(1):170. doi: 10.1002/mus.25182. Muscle Nerve. 2016. PMID: 27297960 Free PMC article. No abstract available.

Abstract

Introduction: Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity were studied.

Methods: Subjects randomized 2:1 to incobotulinumtoxinA (fixed dose 400 U) or placebo, with fixed doses for the primary target clinical pattern (PTCP; flexed elbow, 200 U; flexed wrist, 150 U; clenched fist, 100 U). Doses for non-primary patterns were flexible within predefined ranges.

Results: At week 4, incobotulinumtoxinA led to larger improvements in PTCP Ashworth scale (AS) scores than placebo [least-squares mean change ± standard error: -0.9 ± 0.06 (n = 171) vs. -0.5 ± 0.08 (n = 88); P < 0.001], and more subjects were PTCP AS responders (≥1-point improvement) with incobotulinumtoxinA (69.6%) than with placebo (37.5%; P < 0.001). Investigator's Global Impression of Change confirmed superiority of incobotulinumtoxinA vs. placebo (P = 0.003). IncobotulinumtoxinA was associated with functional improvements, as demonstrated in responder rates for Disability Assessment Scale principal target at week 4 (P = 0.007). Adverse events were mainly mild/moderate, and were reported by 22.4% (incobotulinumtoxinA) and 16.8% (placebo) of subjects.

Conclusions: IncobotulinumtoxinA significantly improved upper-limb spasticity and associated disability, and was well-tolerated.

Keywords: Xeomin; botulinum toxins, type A; incobotulinumtoxinA; muscle spasticity; stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Subject flow diagram. FAS indicates full analysis set; SES indicates safety evaluation set.
Figure 2
Figure 2
Ashworth scale scores. LS mean indicates least‐squares mean. (A) Change from baseline to week 4 for the primary target clinical pattern (PTCP, full analysis set, last observation carried forward). Error bars show the standard error. ** P < 0.001 for incobotulinumtoxinA vs. placebo. (B) Responder analysis for the PTCP over time (full analysis set, worst case imputation). Subjects with an improvement (reduction) of ≥1 point on the Ashworth scale were classified as responders. ** P < 0.001, * P = 0.004 for incobotulinumtoxinA vs. placebo. (C) Responder analysis for each clinical pattern group at week 4 (full analysis set, observed cases). Subjects with an improvement (reduction) of ≥1 point on the Ashworth scale were classified as responders. ** P ≤ 0.001, * P = 0.028 for incobotulinumtoxinA vs. placebo.
Figure 3
Figure 3
Investigator's Global Impression of Change. LS mean indicates least‐squares mean. (A) Mean scores for the primary target clinical pattern (PTCP) at week 4 (full analysis set, worst case imputation). Error bars show the standard error. * P < 0.05 for incobotulinumtoxinA vs. placebo. (B) Frequency distribution for the PTCP 4 weeks after treatment (full analysis set, worst case imputation). P = 0.001 (Wilcoxon rank‐sum test).
See this image and copyright information in PMC

References

    1. Kanovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper‐limb spasticity. Clin Neuropharmacol 2009;32:259–265. - PubMed
    1. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al A randomized, double‐blind, placebo‐controlled, dose‐ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper‐limb spasticity after stroke. Stroke 2000;31:2402–2406. - PubMed
    1. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395–400. - PubMed
    1. Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, et al Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double‐blind, placebo‐controlled trial. Neurology 1996;46:1306–1310. - PubMed
    1. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A, BoNT/TZD Study Team . Botulinum neurotoxin versus tizanidine in upper‐limb spasticity: a placebo‐controlled study. J Neurol Neurosurg Psychiatry 2009;80:380–385. - PubMed

Publication types